SynthesisBMC gastroenterology2024
Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The role of microbiome-modulating supplements in managing metabolic syndrome risk factors among overweight and obese youth: a GRADE-assessed meta-analysis.BMC pediatrics · 2025Pooled it
- The role of gut microbiota in modulating immune responses in chronic liver disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Efficacy of interventions with live combinedFrontiers in pharmacology · 2025Pooled it
- Short term synbiotic supplementation improves hepatic and metabolic outcomes in children with metabolic dysfunction associated steatotic liver disease.Scientific reports · 2026Trial
- Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease: From Dysbiosis to Metagenomic Insights and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Modulating the Gut-Liver Axis: Anti-Inflammatory Mechanisms of Probiotics and Prebiotics in MASLD.Probiotics and antimicrobial proteins · 2026Review
- Mitochondrial Communication with Cellular Organelles in the Pathogenesis of Fatty Liver Disease in Domestic and Model Animals.Animals : an open access journal from MDPI · 2026Review
- Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management.Antioxidants (Basel, Switzerland) · 2026Review
- Mechanisms of postpartum metabolic dysfunction-associated steatotic liver disease in women with a history of gestational diabetes mellitus.Endocrine connections · 2026Review
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets.Probiotics and antimicrobial proteins · 2026Review
- Engineered live bacteria for liver diseases and gut-liver axis disorders: from genetic modification to advanced delivery systems.Journal of nanobiotechnology · 2026Review
- Decoding the gut microbiota-immune dialogue: from bidirectional axis to therapeutic applications.Journal of nanobiotechnology · 2026Review
- Chlorella vulgaris and Lactobacillus casei Improve Liver Dysfunction via UPR and Autophagy in High-Fat Diet-Induced NAFLD in Mice.Probiotics and antimicrobial proteins · 2026Article
- Gut Microbiota Dysbiosis and LPS/NLRP3/GSDMD Pyroptosis Drive Hepatic Fibrosis: Therapeutic Potential of a Synbiotic Intervention.Probiotics and antimicrobial proteins · 2026Article
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- Gut allies against metabolic disorders: the therapeutic promise of probiotics.Folia microbiologica · 2026Review
- Multi-strain synbiotic and lifestyle modifications on patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized double-blinded placebo-controlled trial.European journal of medical research · 2026Article
- Article
- Enhanced Efficacy of Synbiotics Compared to Antibiotics in Promoting Growth, Intestinal Health, and Immune Response in Stinging Catfish.Aquaculture nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThere is a contradiction in the use of microbiota-therapies, including probiotics, prebiotics, and synbiotics, to improve the condition of patients with nonalcoholic fatty liver disease (NAFLD). The aim of this review was to evaluate the effect of microbiota-therapy on liver injury, inflammation, and lipid levels in individuals with NAFLD.
methodsUsing Pubmed, Embase, Cochrane Library, and Web of Science databases were searched for articles on the use of prebiotic, probiotic, or synbiotic for the treatment of patients with NAFLD up to March 2024.
resultsThirty-four studies involving 12,682 individuals were included. Meta-analysis indicated that probiotic, prebiotic, and synbiotic supplementation significantly improved liver injury (hepatic fibrosis, SMD = -0.31; 95% CI: -0.53, -0.09; aspartate aminotransferase, SMD = -0.35; 95% CI: -0.55, -0.15; alanine aminotransferase, SMD = -0.48; 95% CI: -0.71, -0.25; alkaline phosphatase, SMD = -0.81; 95% CI: -1.55, -0.08), lipid profiles (triglycerides, SMD = -0.22; 95% CI: -0.43, -0.02), and inflammatory factors (high-density lipoprotein, SMD = -0.47; 95% CI: -0.88, -0.06; tumour necrosis factor alpha, SMD = -0.86 95% CI: -1.56, -0.56).
conclusionOverall, supplementation with probiotic, prebiotic, or synbiotic had a positive effect on reducing liver enzymes, lipid profiles, and inflammatory cytokines in patients with NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.